A randomized, multicentre, double blind, placebo-controlled trial to evaluate the efficacy and safety of omalizumab in patients with peanut allergy

Trial Profile

A randomized, multicentre, double blind, placebo-controlled trial to evaluate the efficacy and safety of omalizumab in patients with peanut allergy

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2016

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Peanut hypersensitivity
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Mar 2016 New trial record
    • 07 Mar 2016 Results (n=37) presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top